The development of a multimodal antibody platform to extend the window of immunotherapeutic intervention. The overall objective of the work outlined in this contract is to critically evaluate the…
Active Definitive Contract Awarded Last action
- Contract number
- 75A50123C00060
- Awardee
-
Eitr Biologics, Inc. UEI HX49LZLY32G5
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $33,059,642
Award facts
- Contract value 10% obligated
-
- $33,059,642.43 Current, with exercised options
- $317,552,135.13 Potential, with all options
- Completion date 28% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- San Diego, CA 92121, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $1,889,251 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $4,556,214 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $16,964,413 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $9,649,764 |
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract to Eitr Biologics, Inc. for development of a multimodal antibody platform to extend the window of immunotherapeutic intervention on September 22, 2023, with a ceiling value of $317.6 million.
The contract pursues critical evaluation of the VHH (variable domain of heavy chain antibody) as a platform medical countermeasure technology. Work is performed in San Diego, CA. The contract carries cost-plus-fixed-fee pricing and extends through September 30, 2034. No set-aside applies.
Description
The development of a multimodal antibody platform to extend the window of immunotherapeutic intervention. The overall objective of the work outlined in this contract is to critically evaluate the utility of the VHH as a platform MCM technology for VI
Quick answers
Who was awarded contract 75A50123C00060?
75A50123C00060 was awarded to Eitr Biologics, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 22, 2023.
How much is contract 75A50123C00060 worth?
The government has obligated $33,059,642 on 75A50123C00060. Its potential value, with all options, is $317,552,135.
Was contract 75A50123C00060 competed?
The extent of competition for 75A50123C00060 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award